Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma tumor formation in NOD/SCID mice is inhibited by neomycin and neamine blocking angiogenin's nuclear translocation

Journal of Virology

Volumn 87, Issue 21, 2013, Pages 11806-11820

  Bottero, Virginie ^a   Sadagopan, Sathish ^b   Johnson, Karen E ^a   Dutta, Sujoy ^a   Veettil, Mohanan Valiya ^a   Chandran, Bala ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b Anthem Biosciences Pvt Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIN; CELL NUCLEUS ANTIGEN; LATENCY ASSOCIATED NUCLEAR ANTIGEN 1; NEAMINE; NEOMYCIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES; BODY WEIGHT; CELL DEATH; CELL SURVIVAL; ENDOTHELIUM CELL; HUMAN HERPESVIRUS 8; IN VIVO STUDY; NONHUMAN; PATHOGENESIS; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; SPLEEN SIZE;

ANIMALS; ANTINEOPLASTIC AGENTS; ASCITES; BODY WEIGHT; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FRAMYCETIN; HERPESVIRUS 8, HUMAN; LYMPHOMA, PRIMARY EFFUSION; MICE; MICE, SCID; NEOMYCIN; RIBONUCLEASE, PANCREATIC; SPLEEN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84886908565     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01920-13     Document Type: Article

References (94)

1. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869.
2. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 332:1186-1191.
3. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, d'Agay MF, Clauvel JP, Raphael M, Degos L, et al. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86:1276-1280.
4. Green I, Espiritu E, Ladanyi M, Chaponda R, Wieczorek R, Gallo L, Feiner H. 1995. Primary lymphomatous effusions in AIDS: a morphological, immunophenotypic, and molecular study. Mod. Pathol. 8:39-45.
5. Chadburn A, Hyjek E, Mathew S, Cesarman E, Said J, Knowles DM. 2004. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am. J. Surg. Pathol. 28:1401-1416.
6. Carbone A, Gloghini A, Vaccher E, Cerri M, Gaidano G, Dalla-Favera R, Tirelli U. 2005. Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma. J. Mol. Diagn. 7:17-27.
7. Komanduri KV, Luce JA, McGrath MS, Herndier BG, Ng VL. 1996. The natural history and molecular heterogeneity of HIV-associated primary malignant lymphomatous effusions. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 13:215-226.
8. Knowles DM, Inghirami G, Ubriaco A, Dalla-Favera R. 1989. Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the possible pathogenetic role of the Epstein-Barr virus. Blood 73:792-799.
9. Ganem D. 2007. Kaposi's sarcoma-associated herpesvirus, 5th ed, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA.
10. Lallemand F, Desire N, Rozenbaum W, Nicolas JC, Marechal V. 2000. Quantitative analysis of human herpesvirus 8 viral load using a real-time PCR assay. J. Clin. Microbiol. 38:1404-1408.
11. Fakhari FD, Jeong JH, Kanan Y, Dittmer DP. 2006. The latencyassociated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. J. Clin. Invest. 116:735-742.
12. Liu L, Eby MT, Rathore N, Sinha SK, Kumar A, Chaudhary PM. 2002. The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex. J. Biol. Chem. 277:13745-13751.
13. Sun Q, Matta H, Chaudhary PM. 2003. The human herpes virus 8-encoded viral FLICE inhibitory protein protects against growth factor withdrawal- induced apoptosis via NF-kappa B activation. Blood 101:1956-1961.
14. Sun Q, Zachariah S, Chaudhary PM. 2003. The human herpes virus 8-encoded viral FLICE-inhibitory protein induces cellular transformation via NF-kappaB activation. J. Biol. Chem. 278:52437-52445.
15. Guasparri I, Keller SA, Cesarman E. 2004. KSHV vFLIP is essential for the survival of infected lymphoma cells. J. Exp. Med. 199:993-1003.
16. Sadler R, Wu L, Forghani B, Renne R, Zhong W, Herndier B, Ganem D. 1999. A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcomaassociated herpesvirus. J. Virol. 73:5722-5730.
17. McCormick C, Ganem D. 2005. The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science 307:739-741.
18. Rivas C, Thlick AE, Parravicini C, Moore PS, Chang Y. 2001. Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J. Virol. 75:429-438.
19. Gottwein E. 2012. Kaposi's sarcoma-associated herpesvirus microRNAs. Front. Microbiol. 3:165.
20. Ramalingam D, Kieffer-Kwon P, Ziegelbauer JM. 2012. Emerging themes from EBV and KSHV microRNA targets. Viruses 4:1687-1710.
21. Dahlke C, Maul K, Christalla T, Walz N, Schult P, Stocking C, GrundhoffA. 2012. A microRNA encoded by Kaposi sarcoma-associated herpesvirus promotes B-cell expansion in vivo. PLoS One 7:e49435. doi:10.1371/journal.pone.0049435.
22. Fett JW, Strydom DJ, Lobb RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL. 1985. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 24:5480-5486.
23. Strydom DJ, Fett JW, Lobb RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL. 1985. Amino acid sequence of human tumor derived angiogenin. Biochemistry 24:5486-5494.
24. Chopra V, Dinh TV, Hannigan EV. 1996. Angiogenin, interleukins, and growth-factor levels in serum of patients with ovarian cancer: correlation with angiogenesis. Cancer J. Sci. Am. 2:279-285.
25. Chopra V, Dinh TV, Hannigan EV. 1997. Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer. J. Cancer Res. Clin. Oncol. 123:167-172.
26. Chopra V, Dinh TV, Hannigan EV. 1998. Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Invest. 16:152-159.
27. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. 1999. Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence. Cancer 86:316-324.
28. Montero S, Guzman C, Cortes-Funes H, Colomer R. 1998. Angiogenin expression and prognosis in primary breast carcinoma. Clin. Cancer Res. 4:2161-2168.
29. Shimoyama S, Gansauge F, Gansauge S, Negri G, Oohara T, Beger HG. 1996. Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Cancer Res. 56:2703-2706.
30. Shimoyama S, Kaminishi M. 2000. Increased angiogenin expression in gastric cancer correlated with cancer progression. J. Cancer Res. Clin. Oncol. 126:468-474.
31. Shimoyama S, Yamasaki K, Kawahara M, Kaminishi M. 1999. Increased serum angiogenin concentration in colorectal cancer is correlated with cancer progression. Clin. Cancer Res. 5:1125-1130.
32. Hu GF, Riordan JF. 1993. Angiogenin enhances actin acceleration of plasminogen activation. Biochem. Biophys. Res. Commun. 197:682-687.
33. Hu G, Riordan JF, Vallee BL. 1994. Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. Proc. Natl. Acad. Sci. U. S. A. 91:12096-12100.
34. Bicknell R, Vallee BL. 1988. Angiogenin activates endothelial cell phospholipase C. Proc. Natl. Acad. Sci. U. S. A. 85:5961-5965.
35. Kim HM, Kang DK, Kim HY, Kang SS, Chang SI. 2007. Angiogenininduced protein kinase B/Akt activation is necessary for angiogenesis but is independent of nuclear translocation of angiogenin in HUVE cells. Biochem. Biophys. Res. Commun. 352:509-513.
36. Liu S, Yu D, Xu ZP, Riordan JF, Hu GF. 2001. Angiogenin activates Erk1/2 in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 287:305-310.
37. Shapiro R, Riordan JF, Vallee BL. 1986. Characteristic ribonucleolytic activity of human angiogenin. Biochemistry 25:3527-3532.
38. Hu GF. 2001. Neomycin inhibits the angiogenic activity of fibroblast and epidermal growth factors. Biochem. Biophys. Res. Commun. 287:870-874.
39. Moroianu J, Riordan JF. 1994. Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity. Proc. Natl. Acad. Sci. U. S. A. 91:1677-1681.
40. Xu ZP, Tsuji T, Riordan JF, Hu GF. 2003. Identification and characterization of an angiogenin-bindingDNAsequence that stimulates luciferase reporter gene expression. Biochemistry 42:121-128.
41. Williams PD, Bennett DB, Gleason CR, Hottendorf GH. 1987. Correlation between renal membrane binding and nephrotoxicity of aminoglycosides. Antimicrob. Agents Chemother. 31:570-574.
42. Au S, Weiner N, Schacht J. 1986. Membrane perturbation by aminoglycosides as a simple screen of their toxicity. Antimicrob. Agents Chemother. 30:395-397.
43. Hirukawa S, Olson KA, Tsuji T, Hu GF. 2005. Neamine inhibits xenografic human tumor growth and angiogenesis in athymic mice. Clin. Cancer Res. 11:8745-8752.
44. Hu GF. 1998. Neomycin inhibits angiogenin-induced angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 95:9791-9795.
45. Gabev E, Kasianowicz J, Abbott T, McLaughlin S. 1989. Binding of neomycin to phosphatidylinositol 4,5-bisphosphate (PIP2). Biochim. Biophys. Acta 979:105-112.
46. Sadagopan S, Veettil MV, Paudel N, Bottero V, Chandran B. 2011. Kaposi's sarcoma-associated herpesvirus (KSHV) induced angiogenin plays roles in latency via PLC{gamma} pathway and blocking angiogenin inhibits latent gene expression and induces the lytic cycle. J. Virol. 85: 2666-2685.
47. Sadagopan S, Sharma-Walia N, Veettil MV, Bottero V, Levine R, Vart RJ, Chandran B. 2009. Kaposi's sarcoma-associated herpesvirus upregulates angiogenin during infection of human dermal microvascular endothelial cells, which induces 45S rRNA synthesis, antiapoptosis, cell proliferation, migration, and angiogenesis. J. Virol. 83:3342-3364.
48. Paudel N, Sadagopan S, Chakraborty S, Sarek G, Ojala PM, Chandran B. 2012. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with multifunctional angiogenin to utilize its antiapoptotic functions. J. Virol. 86:5974-5991.
49. Fett JW, Olson KA, Rybak SM. 1994. A monoclonal antibody to human angiogenin. Inhibition of ribonucleolytic and angiogenic activities and localization of the antigenic epitope. Biochemistry 33:5421-5427.
50. Olson KA, French TC, Vallee BL, Fett JW. 1994. A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice. Cancer Res. 54:4576-4579.
51. Sadagopan S, Veettil MV, Chakraborty S, Sharma-Walia N, Paudel N, Bottero V, Chandran B. 2012. Angiogenin functionally interacts with p53 and regulates p53-mediated apoptosis and cell survival. Oncogene 31: 4835-4847.
52. Wang FZ, Akula SM, Sharma-Walia N, Zeng L, Chandran B. 2003. Human herpesvirus 8 envelope glycoprotein B mediates cell adhesion via its RGD sequence. J. Virol. 77:3131-3147.
53. Akula SM, Naranatt PP, Walia NS, Wang FZ, Fegley B, Chandran B. 2003. Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) infection of human fibroblast cells occurs through endocytosis. J. Virol. 77:7978-7990.
54. Akula SM, Pramod NP, Wang FZ, Chandran B. 2002. Integrin alpha3beta1 (CD 49c/29) is a cellular receptor for Kaposi's sarcomaassociated herpesvirus (KSHV/HHV-8) entry into the target cells. Cell 108:407-419.
55. Naranatt PP, Akula SM, Zien CA, Krishnan HH, Chandran B. 2003. Kaposi's sarcoma-associated herpesvirus induces the phosphatidylinositol 3-kinase-PKC-zeta-MEK-ERK signaling pathway in target cells early during infection: implications for infectivity. J. Virol. 77:1524-1539.
56. Bewick V, Cheek L, Ball J. 2004. Statistics review 12: survival analysis. Crit. Care 8:389-394.
57. Krishnan HH, Naranatt PP, Smith MS, Zeng L, Bloomer C, Chandran B. 2004. Concurrent expression of latent and a limited number of lytic genes with immune modulation and antiapoptotic function by Kaposi's sarcoma-associated herpesvirus early during infection of primary endothelial and fibroblast cells and subsequent decline of lytic gene expression. J. Virol. 78:3601-3620.
58. Sadagopan S, Sharma-Walia N, Veettil MV, Raghu H, Sivakumar R, Bottero V, Chandran B. 2007. Kaposi's sarcoma-associated herpesvirus induces sustained NF-kappaB activation during de novo infection of primary human dermal microvascular endothelial cells that is essential for viral gene expression. J. Virol. 81:3949-3968.
59. Paul AG, Sharma-Walia N, Chandran B. 2011. Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma. PLoS One 6:e24379. doi:10.1371/journal.pone.0024379.
60. Roy D, Dittmer DP. 2011. Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma. Am. J. Pathol. 179:2108-2119.
61. BoshoffC, Gao SJ, Healy LE, Matthews S, Thomas AJ, Coignet L, Warnke RA, Strauchen JA, Matutes E, Kamel OW, Moore PS, Weiss RA, Chang Y. 1998. Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. Blood 91:1671-1679.
62. Picchio GR, Sabbe RE, Gulizia RJ, McGrath M, Herndier BG, Mosier DE. 1997. The KSHV/HHV8-infected BCBL-1 lymphoma line causes tumors in SCID mice but fails to transmit virus to a human peripheral blood mononuclear cell graft. Virology 238:22-29.
63. Li S, Yu W, Kishikawa H, Hu GF. 2010. Angiogenin prevents serum withdrawal-induced apoptosis of P19 embryonal carcinoma cells. FEBS J. 277:3575-3587.
64. Li S, Yu W, Hu GF. 2012. Angiogenin inhibits nuclear translocation of apoptosis inducing factor in a Bcl-2-dependent manner. J. Cell. Physiol. 227:1639-1644.
65. Keller SA, Schattner EJ, Cesarman E. 2000. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 96:2537-2542.
66. Keller SA, Hernandez-Hopkins D, Vider J, Ponomarev V, Hyjek E, Schattner EJ, Cesarman E. 2006. NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood 107:3295-3302.
67. An J, Sun Y, Fisher M, Rettig MB. 2004. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 18:1699-1704.
68. Abou-Merhi R, Khoriaty R, Arnoult D, El Hajj H, Dbouk H, Munier S, El-Sabban ME, Hermine O, Gessain A, de The H, Mahieux R, Bazarbachi A. 2007. PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV- 8-infected primary effusion lymphoma cells. Leukemia 21:1792-1801.
69. Sarosiek KA, Cavallin LE, Bhatt S, Toomey NL, Natkunam Y, Blasini W, Gentles AJ, Ramos JC, Mesri EA, Lossos IS. 2012. Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Proc. Natl. Acad. Sci. U. S. A. 107:13069-13074.
70. Dabaghmanesh N, Matsubara A, Miyake A, Nakano K, Ishida T, Katano H, Horie R, Umezawa K, Watanabe T. 2009. Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation. Cancer Sci. 100:737-746.
71. Takahashi-Makise N, Suzu S, Hiyoshi M, Ohsugi T, Katano H, Umezawa K, Okada S. 2009. Biscoclaurine alkaloid cepharanthine inhibits the growth of primary effusion lymphoma in vitro and in vivo and induces apoptosis via suppression of the NF-kappaB pathway. Int. J. Cancer 125:1464-1472.
72. Bhatt AP, Damania B. 2012. AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV. Front. Immunol. 3:401.
73. Bhatt AP, Jacobs SR, Freemerman AJ, Makowski L, Rathmell JC, Dittmer DP, Damania B. 2012. Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma. Proc. Natl. Acad. Sci. U. S. A. 109: 11818-11823.
74. Paudel N, Sadagopan S, Balasubramanian S, Chandran B. 2012. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen and angiogenin interact with common host proteins, including annexin A2, which is essential for survival of latently infected cells. J. Virol. 86: 1589-1607.
75. Friborg J, Jr, Kong W, Hottiger MO, Nabel GJ. 1999. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 402:889-894.
76. Chen W, Hilton IB, Staudt MR, Burd CE, Dittmer DP. 2010. Distinct p53, p53:LANA, and LANA complexes in Kaposi's sarcoma-associated herpesvirus lymphomas. J. Virol. 84:3898-3908.
77. Si H, Robertson ES. 2006. Kaposi's sarcoma-associated herpesvirusencoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J. Virol. 80:697-709.
78. Chaudhary PM, Jasmin A, Eby MT, Hood L. 1999. Modulation of the NF-kappa B pathway by virally encoded death effector domainscontaining proteins. Oncogene 18:5738-5746.
79. Suffert G, Malterer G, Hausser J, Viiliainen J, Fender A, Contrant M, Ivacevic T, Benes V, Gros F, Voinnet O, Zavolan M, Ojala PM, Haas JG, Pfeffer S. 2011. Kaposi's sarcoma herpesvirus microRNAs target caspase 3 and regulate apoptosis. PLoS Pathog. 7:e1002405. doi:10.1371/journal.ppat.1002405.
80. Haecker I, Gay LA, Yang Y, Hu J, Morse AM, McIntyre LM, Renne R. 2012. Ago HITS-CLIP expands understanding of Kaposi's sarcomaassociated herpesvirus miRNA function in primary effusion lymphomas. PLoS Pathog. 8:e1002884. doi:10.1371/journal.ppat.1002884.
81. Gottwein E, Corcoran DL, Mukherjee N, Skalsky RL, Hafner M, Nusbaum JD, Shamulailatpam P, Love CL, Dave SS, Tuschl T, Ohler U, Cullen BR. 2011. Viral microRNA targetome of KSHV-infected primary effusion lymphoma cell lines. Cell Host Microbe 10:515-526.
82. Yuan Y, Wang F, Liu XH, Gong DJ, Cheng HZ, Huang SD. 2009. Angiogenin is involved in lung adenocarcinoma cell proliferation and angiogenesis. Lung Cancer 66:28-36.
83. Yoshioka N, Wang L, Kishimoto K, Tsuji T, Hu GF. 2006. A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 103:14519-14524.
84. Ibaragi S, Yoshioka N, Kishikawa H, Hu JK, Sadow PM, Li M, Hu GF. 2009. Angiogenin-stimulated rRNA transcription is essential for initiation and survival of AKT-induced prostate intraepithelial neoplasia. Mol. Cancer Res. 7:415-424.
85. Curran TP, Shapiro R, Riordan JF, Vallee BL. 1993. Modulation of the activity of angiogenin by mutagenesis at Asp-116. Biochim. Biophys. Acta 1202:281-286.
86. Hallahan TW, Shapiro R, Strydom DJ, Vallee BL. 1992. Importance of asparagine-61 and asparagine-109 to the angiogenic activity of human angiogenin. Biochemistry 31:8022-8029.
87. Harper JW, Fox EA, Shapiro R, Vallee BL. 1990. Mutagenesis of residues flanking Lys-40 enhances the enzymatic activity and reduces the angiogenic potency of angiogenin. Biochemistry 29:7297-7302.
88. Shapiro R, Fox EA, Riordan JF. 1989. Role of lysines in human angiogenin: chemical modification and site-directed mutagenesis. Biochemistry 28:1726-1732.
89. Shapiro R, Vallee BL. 1989. Site-directed mutagenesis of histidine-13 and histidine-114 of human angiogenin. Alanine derivatives inhibit angiogenin- induced angiogenesis. Biochemistry 28:7401-7408.
90. Shapiro R, Vallee BL. 1992. Identification of functional arginines in human angiogenin by site-directed mutagenesis. Biochemistry 31:12477-12485.
91. Kao RY, Jenkins JL, Olson KA, Key ME, Fett JW, Shapiro R. 2002. A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity. Proc. Natl. Acad. Sci. U. S. A. 99:10066-10071.
92. Zhao J, Wang YC, Yang LY, Yu DH, Pan PT, Wang L. 2012. Neamine inhibits cell proliferation, migration, and invasion in H7402 human hepatoma cells. Saudi Med. J. 31:1309-1314.
93. Piccoli R, Olson KA, Vallee BL, Fett JW. 1998. Chimeric anti-angiogenin antibody cAb 26-2F inhibits the formation of human breast cancer xenografts in athymic mice. Proc. Natl. Acad. Sci. U. S. A. 95:4579-4583.
94. Dittmer DP, Damania B. 2013. Kaposi sarcoma associated herpesvirus pathogenesis (KSHV)-an update. Curr. Opin. Virol. 3:238-244.